Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.41 | ||
| Price to Tang. Book | 4.51 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.57 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -76.07% | ||
| Return on Equity | -76.55% | ||
| Operating Margin | -45.48% | ||
Financial Summary
| Year End 31st Mar | Unit | 2022 | 2023 | 2024 | 2025 | 2026 | 2027E | 2028E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | ¥m | 11,555.09 | 12,517 | 12,307.87 | 10,437.03 | 8,665.82 | 13,000 | n/a | -3.36% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +27.71 | +8.33 | -40.13 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Linical Co., Ltd. is a Japan-based company mainly engaged in the contract research organization (CRO) business for drug companies. The Company operates in two businesses. The CRO segment is engaged in the provision of contract monitoring, quality management and consulting services for phase II and phase III in drug development processes. The Pharmaceutical Sales Support segment is engaged in provision of pharmaceutical sales support for medical institutions in the downstream market.
Directors
- Kazuhiro Hatano PRE (49)
- Akihiro Takahashi CFO (47)
- Keigo Tsujimoto VPR (50)
- Jun Kawai SMD (44)
- Yoshio Kaji MDR (56)
- Masaya Miyazaki MDR (41)
- Isao Sakamoto OTH (38)
- Shiori Yamaguchi OTH (37)
- Kazuhiro Tajiri DRC (55)
- Masafumi Nogimori IND (69)
- Akio Ohsawa IND (75)
- Last Annual
- March 31st, 2026
- Last Interim
- June 30th, 2026
- Incorporated
- June 7th, 2005
- Public Since
- October 27th, 2008
- No. of Shareholders
- 5,937
- No. of Employees
- 577
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Tokyo Stock Exchange- Shares in Issue
- 22,586,431
- Address
- 10F, Shin-Osaka Brick Bldg, OSAKA-SHI, 532-0003
- Web
- https://www.linical.com/
- Phone
- +81 661502478
- Auditors
- Deloitte Touche Tohmatsu LLC
Latest News for 2183
Upcoming Events for 2183
Q2 2027 Linical Co Ltd Earnings Release
Dividend For 2183.T - 8.0000 JPY
Similar to 2183
3-D Matrix
Tokyo Stock Exchange
ADR Biomedical Holdings
Tokyo Stock Exchange
AnGes
Tokyo Stock Exchange
BrightPath Biotherapeutics
Tokyo Stock Exchange
Carna Biosciences
Tokyo Stock Exchange
FAQ
As of Today at 21:47 UTC, shares in Linical are trading at ¥200. This share price information is delayed by 15 minutes.
Shares in Linical last closed at ¥200 and the price had moved by -40.83% over the past 365 days. In terms of relative price strength the Linical share price has underperformed the Nikkei 225 Index by -54.09% over the past year.
The overall consensus recommendation for Linical is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Linical dividend yield is 4% based on the trailing twelve month period.
Last year, Linical paid a total dividend of ¥8, and it currently has a trailing dividend yield of 4%. We do not have any data on when Linical is to next pay dividends.
We do not have data on when Linical is to next pay dividends. The historic dividend yield on Linical shares is currently 4%.
To buy shares in Linical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥200, shares in Linical had a market capitalisation of ¥5bn.
Here are the trading details for Linical:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 2183
Based on an overall assessment of its quality, value and momentum Linical is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Linical is ¥1,300. That is 550% above the last closing price of ¥200.
Analysts covering Linical currently have a consensus Earnings Per Share (EPS) forecast of ¥30 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Linical. Over the past six months, its share price has underperformed the Nikkei 225 Index by -22.75%.
As of the last closing price of ¥200, shares in Linical were trading -18.31% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Linical PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥200.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Linical's management team is headed by:
- Kazuhiro Hatano - PRE
- Akihiro Takahashi - CFO
- Keigo Tsujimoto - VPR
- Jun Kawai - SMD
- Yoshio Kaji - MDR
- Masaya Miyazaki - MDR
- Isao Sakamoto - OTH
- Shiori Yamaguchi - OTH
- Kazuhiro Tajiri - DRC
- Masafumi Nogimori - IND
- Akio Ohsawa - IND